European Union - English - EMA (European Medicines Agency)

biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - mucopolysaccharidosis iv - other alimentary tract and metabolism products, - vimizim is indicated for the treatment of mucopolysaccharidosis, type iva (morquio a syndrome, mps iva) in patients of all ages.

Canada - English - Health Canada

biomarin international limited - elosulfase alfa - solution - 1mg - elosulfase alfa 1mg - enzymes

Israel - English - Ministry of Health

medison pharma ltd - elosulfase alfa - concentrate for solution for infusion - elosulfase alfa 1 mg/ml - elosulfase alfa - vimizim is indicated for the treatment of mucopolysaccharidosis, type iva (morquio a syndrome ,mps iva) in patients of all ages.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (united states - elosulfase alfa - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

biomarin europe ltd - elosulfase alfa - solution for infusion - 1mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - elosulfase alfa 1 mg/ml;   - concentrate for injection - 1 mg/ml - active: elosulfase alfa 1 mg/ml   excipient: arginine hydrochloride monobasic sodium phosphate monohydrate polysorbate 20 sodium acetate trihydrate sorbitol water for injection - treatment of mucopolysaccharidosis type iva (mps iva; morquio a syndrome) in children and adults of all ages.